Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + pembrolizumab for HER2-positive platinum‑resistant recurrent epithelial ovarian cancer (phase II, Union Hospital Tongji)
ChiCTR2500101965Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pembrolizumab in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Union Hospital. Primary endpoint: Objective Response Rate. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2500101965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101965.